Yousif Capital Management LLC Has $850,000 Stock Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Yousif Capital Management LLC cut its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 2.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,631 shares of the company’s stock after selling 323 shares during the period. Yousif Capital Management LLC’s holdings in TransMedics Group were worth $850,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. NBC Securities Inc. acquired a new position in TransMedics Group in the 1st quarter valued at about $25,000. Atlas Capital Advisors Inc. acquired a new position in TransMedics Group in the 4th quarter valued at about $31,000. AlphaQuest LLC acquired a new position in TransMedics Group in the 4th quarter valued at about $52,000. Arcadia Investment Management Corp MI acquired a new position in TransMedics Group in the 4th quarter valued at about $72,000. Finally, Rakuten Securities Inc. grew its stake in TransMedics Group by 68.3% in the 4th quarter. Rakuten Securities Inc. now owns 1,355 shares of the company’s stock valued at $84,000 after buying an additional 550 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Oppenheimer upped their price target on shares of TransMedics Group from $130.00 to $150.00 and gave the company an “outperform” rating in a research note on Tuesday. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research note on Tuesday. Piper Sandler reiterated an “overweight” rating and issued a $145.00 price target (up previously from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $104.00 target price on shares of TransMedics Group in a research report on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $127.33.

TransMedics Group Stock Performance

Shares of NASDAQ:TMDX opened at $124.00 on Friday. The company’s 50 day moving average price is $113.37 and its two-hundred day moving average price is $83.69. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37. The firm has a market cap of $4.19 billion, a PE ratio of 91.18 and a beta of 2.10. The company has a quick ratio of 8.32, a current ratio of 9.10 and a debt-to-equity ratio of 1.92.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.29 by $0.41. TransMedics Group had a net margin of 10.03% and a return on equity of 21.88%. The firm had revenue of $143.54 million for the quarter, compared to analyst estimates of $123.39 million. During the same quarter in the prior year, the business posted $0.35 EPS. The business’s revenue was up 48.2% compared to the same quarter last year. Equities research analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insider Transactions at TransMedics Group

In other news, insider Anil P. Ranganath sold 686 shares of the company’s stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $139.80, for a total transaction of $95,902.80. Following the completion of the sale, the insider now owns 13,955 shares of the company’s stock, valued at approximately $1,950,909. This represents a 4.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Edward M. Basile sold 6,000 shares of the company’s stock in a transaction that occurred on Friday, May 9th. The stock was sold at an average price of $115.63, for a total transaction of $693,780.00. Following the sale, the director now directly owns 732 shares of the company’s stock, valued at approximately $84,641.16. This trade represents a 89.13% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 12,418 shares of company stock valued at $1,512,613. Company insiders own 7.00% of the company’s stock.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.